Once-daily saquinavir (SAQ)/ritonavir (RTV) (2000/100 mg) with abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/300 mg) in naïve patients (2008)
Bickel, M,
Bodtlaender, A,
Knecht, G,
Kurowski, M,
Klauke, S,
Lutz, T
No abstract available.
Antiretroviral tolerability and efficacy after switch to saquinavir in PI-experienced patients: 48-week analysis of the German Rainbow Cohort (2008)
Stephan, C,
Jaeger, H,
Carganico, A,
Knecht, G,
Lutz, T,
Mayr, C,
...
No abstract available.
The Rainbow Cohort: saquinavir/r is effective and well tolerated in antiretroviral therapy (ART)-naïve patients – 48-week results from Germany (2008)
Knechten, H,
Stephan, C,
Lutz, T,
Stoehr, A,
Carganico, A,
Knecht, G,
...
No abstract available.
Lipometabolic side-effects of three ritonavir-boosted double protease inhibitor regimens without reverse transcriptase inhibitors (2008)
Wendig, A,
Stephan, C,
Khaykin, P,
Bickel, M,
Lennemann, T,
Knecht, G,
...
No abstract available.